CN1178941C - Crf受体拮抗剂以及与其有关的方法 - Google Patents

Crf受体拮抗剂以及与其有关的方法 Download PDF

Info

Publication number
CN1178941C
CN1178941C CNB998131725A CN99813172A CN1178941C CN 1178941 C CN1178941 C CN 1178941C CN B998131725 A CNB998131725 A CN B998131725A CN 99813172 A CN99813172 A CN 99813172A CN 1178941 C CN1178941 C CN 1178941C
Authority
CN
China
Prior art keywords
alkyl
ethyl
methyl
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998131725A
Other languages
English (en)
Chinese (zh)
Other versions
CN1326458A (zh
Inventor
M
M·哈达彻
¿
郭志强
J·R·穆卡赛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CN1326458A publication Critical patent/CN1326458A/zh
Application granted granted Critical
Publication of CN1178941C publication Critical patent/CN1178941C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB998131725A 1998-11-12 1999-11-12 Crf受体拮抗剂以及与其有关的方法 Expired - Fee Related CN1178941C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19095898A 1998-11-12 1998-11-12
US09/190,958 1998-11-12
US40074499A 1999-09-21 1999-09-21
US09/400,744 1999-09-21

Publications (2)

Publication Number Publication Date
CN1326458A CN1326458A (zh) 2001-12-12
CN1178941C true CN1178941C (zh) 2004-12-08

Family

ID=26886600

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998131725A Expired - Fee Related CN1178941C (zh) 1998-11-12 1999-11-12 Crf受体拮抗剂以及与其有关的方法

Country Status (19)

Country Link
US (3) US6348466B1 (https=)
EP (1) EP1129096B1 (https=)
JP (1) JP2002529469A (https=)
KR (1) KR20010080402A (https=)
CN (1) CN1178941C (https=)
AT (1) ATE240958T1 (https=)
AU (1) AU755997B2 (https=)
BR (1) BR9915129A (https=)
CA (1) CA2349904A1 (https=)
DE (1) DE69908173T2 (https=)
DK (1) DK1129096T3 (https=)
ES (1) ES2196898T3 (https=)
HK (1) HK1038925B (https=)
IL (1) IL143105A0 (https=)
NO (1) NO20012228L (https=)
NZ (1) NZ511267A (https=)
PT (1) PT1129096E (https=)
TR (1) TR200102178T2 (https=)
WO (1) WO2000027850A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001232271A1 (en) * 2000-02-14 2001-08-20 Japan Tobacco Inc. Preventives/remedies for postoperative stress
EP1278751A1 (en) * 2000-05-01 2003-01-29 Bristol-Myers Squibb Pharma Company Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
US6500839B2 (en) 2000-05-18 2002-12-31 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
AU2001263329A1 (en) * 2000-05-18 2001-11-26 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
DE60126134T2 (de) * 2000-11-03 2007-10-18 Neurocrine Biosciences, Inc., San Diego CRF-Rezeptorantagonisten und Verfahren, die damit in Beziehung stehen
WO2002064592A1 (en) * 2000-12-28 2002-08-22 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists
ATE375345T1 (de) 2000-12-28 2007-10-15 Ono Pharmaceutical Co Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-verbindun als crf-rezeptor antagonist
AU2002249474B2 (en) * 2001-04-30 2006-01-12 Glaxo Group Limited Crf receptor antagonists
US7273871B2 (en) 2001-07-17 2007-09-25 Sb Pharmco Puerto Rico Inc. Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists
GB0117395D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
BRPI0411923A (pt) 2003-06-25 2006-08-15 Ono Pharmaceutical Co sal de ácido metanossulfÈnico de composto pirazolopirimidina, cristal do mesmo e processo de produção do mesmo
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2
US20070293508A1 (en) * 2003-12-22 2007-12-20 Sb Pharmco Puerto Rico Inc And Neurocrine Biosciences, Inc. Crf Receptor Antagonists and Methods Relating Thereto
CA2568967A1 (en) 2004-06-03 2005-12-15 Athlomics Pty Ltd Agents and methods for diagnosing stress
CA2576435A1 (en) * 2004-08-09 2006-03-23 Research Development Foundation Determination of the 3d-structure of an extracellular domain of a b1 g-protein coupled receptor by nmr analysis
DK2135608T3 (da) 2004-08-25 2012-01-23 Ardea Biosciences Inc S-triazolyl-alfa-mercaptoacetanilider som inhibitorer for HIV-revers transkriptase
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
AU2006244195B2 (en) 2005-05-05 2012-03-15 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
EP2132211A4 (en) 2006-11-09 2011-12-07 Ardea Biosciences Inc 4-CYANPHENYLAMINO-SUBSTITUTED BICYCLIC AND HETEROCYCLIC COMPOUNDS AS AN HIV HEMMER
ME01294B (me) 2007-11-27 2013-06-20 Ardea Biosciences Inc Nova jedinjenja i kompozicije i metode upotrebe
ES2389752T3 (es) 2007-12-14 2012-10-31 Ardea Biosciences, Inc. Inhibidores de la transcriptasa inversa

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5013737A (en) * 1988-02-22 1991-05-07 American Cyanamid Company 2,4,8-Trisubstituted-3H,6H-1,4,5A,8A-tetraazaacenaphtylene-3,5-(4H)-diones and 2,4-8-trisubstituted-4,5-dihydro-5-thioxo-3H,6H-1,4,5A,8A-tetrazaacenaphthylen-3-ones
US4904658A (en) 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
RU2130453C1 (ru) 1992-12-17 1999-05-20 Пфайзер Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, способ лечения, промежуточный продукт
CZ284157B6 (cs) 1992-12-17 1998-08-12 Pfizer Inc. Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
KR19990067704A (ko) 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
DK0765327T3 (da) * 1994-06-16 1999-11-29 Pfizer Pyrazolo- og pyrrolopyridiner
EP0770080B1 (en) 1995-05-12 1999-07-14 Neurogen Corporation Novel deazapurine derivatives; a new class of crf1 specific ligands
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
JP2000507552A (ja) 1996-03-26 2000-06-20 デュポン ファーマシューティカルズ カンパニー アリールオキシおよびアリールチオ縮合ピリジン、アリールオキシおよびアリールチオ縮合ピリミジン、およびそれらの誘導体
US6326368B1 (en) 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
HU229024B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
BR9710808A (pt) 1996-08-06 1999-08-17 Pfizer Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
JP3621706B2 (ja) * 1996-08-28 2005-02-16 ファイザー・インク 置換された６，５―ヘテロ―二環式誘導体
US6159980A (en) 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US5760225A (en) 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands

Also Published As

Publication number Publication date
DK1129096T3 (da) 2003-09-15
DE69908173T2 (de) 2004-08-19
EP1129096B1 (en) 2003-05-21
NO20012228D0 (no) 2001-05-04
KR20010080402A (ko) 2001-08-22
ES2196898T3 (es) 2003-12-16
HK1038925B (en) 2003-12-05
BR9915129A (pt) 2001-08-07
US20020143008A1 (en) 2002-10-03
CA2349904A1 (en) 2000-05-18
ATE240958T1 (de) 2003-06-15
TR200102178T2 (tr) 2002-01-21
HK1038925A1 (en) 2002-04-04
IL143105A0 (en) 2002-04-21
DE69908173D1 (de) 2003-06-26
AU755997B2 (en) 2003-01-02
PT1129096E (pt) 2003-09-30
US20040229879A1 (en) 2004-11-18
CN1326458A (zh) 2001-12-12
NZ511267A (en) 2002-12-20
NO20012228L (no) 2001-05-04
US6348466B1 (en) 2002-02-19
JP2002529469A (ja) 2002-09-10
AU1819900A (en) 2000-05-29
WO2000027850A3 (en) 2000-08-03
WO2000027850A2 (en) 2000-05-18
US6723721B2 (en) 2004-04-20
EP1129096A2 (en) 2001-09-05

Similar Documents

Publication Publication Date Title
CN1178941C (zh) Crf受体拮抗剂以及与其有关的方法
AU2001283955B2 (en) Piperazine derivatives
KR101292348B1 (ko) 피리딘 유도체 및 그의 정신병적 장애의 치료에 있어서의용도
ES2247478T3 (es) Azolo-pirimidinas.
JP6928629B2 (ja) Ｃｎｓ疾患を治療するための縮合ジヒドロ−４ｈ−ピラゾロ［５，１−ｃ］［１，４］オキサジニル化合物およびアナログ
CN1097054C (zh) 三环类吡唑衍生物及其组合物
EP3112370A1 (en) Tricyclic heterocyclic compounds and jak inhibitors
EP1637521A1 (en) Novel tricyclic heterocycle compound
CN1328559A (zh) Crf受体拮抗剂以及与其有关的方法
CN1692116A (zh) 腺苷A2a受体拮抗剂
CN1246860A (zh) 3－芳基取代的吡唑并[4,3－d]嘧啶衍生物;促肾上腺皮质激素释放因子受体(CRF1 )特异性配体
CN103717593A (zh) 调节激酶的组合物和方法
CN1784230A (zh) 烟碱性乙酰胆碱受体的正向调节剂
WO2002072101A1 (en) A corticotropin releasing factor receptor ligand, its enantiomer and pharmaceutically acceptable salts
JP2024520396A (ja) 置換されるカルバメート大環状化合物および関連のある治療方法
WO2006068164A1 (ja) 三環式化合物およびその用途
JP2003533530A (ja) Ｃｒｆレセプターアンタゴニスト
ES2207614T3 (es) Antagonistas del receptor de crf y metodos relacionados con estos.
US10562852B2 (en) Crystalline forms of (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile
CN1867548A (zh) 3－氮杂双环[3.1.0]己烷衍生物的制备
CN1809574A (zh) 喹啉3－氨基苯并二氢吡喃衍生物
MXPA01004800A (en) Crf receptor antagonists and methods relating thereto
ZA200104442B (en) CRF receptor antagonists and methods relating thereto.
HK1025958B (en) 3-aryl substituted pyrazolo[4,3-d]pyrimidine derivatives; corticotropin-releasing factor receptor (crf1) specific ligands
HK1093977A (en) Preparation of 3-azabicyclo [3.1.0] hexane derivatives

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee